Dr Lal Pathlabs Ltd
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]
- Market Cap ₹ 24,537 Cr.
- Current Price ₹ 2,924
- High / Low ₹ 3,654 / 1,943
- Stock P/E 56.3
- Book Value ₹ 248
- Dividend Yield 0.82 %
- ROCE 27.1 %
- ROE 21.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 28.4%
Cons
- Stock is trading at 11.8 times its book value
- Promoter holding has decreased over last quarter: -0.68%
- The company has delivered a poor sales growth of 11.0% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of BSE 250 SmallCap Index Nifty Midcap150 Quality 50 BSE 400 MidSmallCap Index Nifty Total Market BSE SmallCap Select Index
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
421 | 541 | 637 | 765 | 882 | 1,024 | 1,165 | 1,274 | 1,491 | 1,879 | 1,769 | 1,967 | 2,073 | |
334 | 406 | 486 | 562 | 651 | 768 | 882 | 946 | 1,083 | 1,366 | 1,308 | 1,408 | 1,473 | |
Operating Profit | 87 | 135 | 151 | 204 | 230 | 256 | 283 | 328 | 408 | 512 | 461 | 559 | 600 |
OPM % | 21% | 25% | 24% | 27% | 26% | 25% | 24% | 26% | 27% | 27% | 26% | 28% | 29% |
3 | 8 | 17 | 20 | 28 | 31 | 46 | 58 | 51 | 53 | 47 | 60 | 82 | |
Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 15 | 15 | 29 | 34 | 27 | 23 |
Depreciation | 18 | 31 | 32 | 32 | 26 | 31 | 36 | 68 | 70 | 76 | 82 | 77 | 75 |
Profit before tax | 71 | 111 | 135 | 192 | 231 | 256 | 292 | 303 | 374 | 461 | 391 | 516 | 584 |
Tax % | 31% | 34% | 32% | 34% | 34% | 34% | 33% | 26% | 25% | 25% | 25% | 26% | |
49 | 74 | 92 | 126 | 152 | 168 | 195 | 223 | 280 | 345 | 292 | 384 | 436 | |
EPS in Rs | 1,456.93 | 137.77 | 16.80 | 15.21 | 18.36 | 20.19 | 23.45 | 26.78 | 33.61 | 41.42 | 35.07 | 46.04 | 52.20 |
Dividend Payout % | 11% | 8% | 9% | 16% | 16% | 22% | 26% | 45% | 60% | 29% | 17% | 39% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 11% |
3 Years: | 10% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 14% |
3 Years: | 11% |
TTM: | 28% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | -6% |
1 Year: | 13% |
Return on Equity | |
---|---|
10 Years: | 24% |
5 Years: | 22% |
3 Years: | 22% |
Last Year: | 21% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3 | 54 | 55 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 |
Reserves | 147 | 135 | 238 | 397 | 503 | 693 | 847 | 933 | 1,134 | 1,389 | 1,606 | 1,816 | 1,991 |
2 | 27 | 27 | 0 | 0 | 0 | 0 | 0 | 38 | 385 | 281 | 136 | 181 | |
100 | 116 | 130 | 112 | 90 | 119 | 136 | 302 | 318 | 354 | 350 | 380 | 324 | |
Total Liabilities | 252 | 331 | 449 | 592 | 676 | 896 | 1,067 | 1,318 | 1,573 | 2,211 | 2,320 | 2,415 | 2,579 |
91 | 114 | 119 | 130 | 121 | 173 | 173 | 297 | 300 | 371 | 361 | 343 | 334 | |
CWIP | 1 | 0 | 1 | 4 | 17 | 9 | 3 | 11 | 9 | 14 | 5 | 6 | 1 |
Investments | 80 | 20 | 49 | 74 | 134 | 174 | 214 | 253 | 171 | 1,062 | 1,213 | 1,143 | 1,274 |
80 | 197 | 280 | 384 | 404 | 540 | 677 | 757 | 1,093 | 764 | 740 | 924 | 969 | |
Total Assets | 252 | 331 | 449 | 592 | 676 | 896 | 1,067 | 1,318 | 1,573 | 2,211 | 2,320 | 2,415 | 2,579 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
79 | 96 | 94 | 142 | 167 | 189 | 208 | 272 | 373 | 426 | 428 | 478 | |
-56 | -86 | -86 | -148 | -134 | -166 | -93 | -19 | -195 | -449 | -288 | 32 | |
-15 | -10 | 1 | 1 | -32 | 13 | -54 | -187 | -136 | 141 | -270 | -404 | |
Net Cash Flow | 9 | 0 | 9 | -5 | 1 | 36 | 61 | 65 | 42 | 118 | -131 | 106 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 17 | 16 | 17 | 17 | 17 | 14 | 17 | 14 | 16 | 13 | 13 | 14 |
Inventory Days | 37 | 31 | 33 | 44 | 40 | 70 | 38 | 32 | 22 | 26 | ||
Days Payable | 89 | 88 | 97 | 104 | 110 | 143 | 132 | 101 | 131 | 156 | ||
Cash Conversion Cycle | 17 | 16 | -35 | -41 | -47 | -45 | -54 | -59 | -79 | -55 | -96 | -116 |
Working Capital Days | -38 | -28 | -10 | 28 | 15 | 18 | 1 | -16 | -16 | -15 | -21 | -22 |
ROCE % | 54% | 61% | 51% | 48% | 44% | 38% | 34% | 33% | 34% | 31% | 22% | 27% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
18 Dec - For Allotment of Equity Shares under Employee Stock Option Plan 2010
- Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 5 Dec
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 26 Nov
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
19 Nov - Schedule of Analyst/Institutional Investor meetings on November 25, 2024.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 7 Nov
Annual reports
Concalls
-
Oct 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jul 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jul 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
May 2021TranscriptNotesPPT
-
Feb 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Jan 2021TranscriptNotesPPT
-
Dec 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Nov 2020TranscriptNotesPPT
-
Aug 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptPPT
-
Jun 2020Transcript PPT
-
May 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptPPT
-
Nov 2019Transcript PPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
Aug 2019TranscriptNotesPPT
-
Jun 2019TranscriptPPT
-
Jun 2019Transcript PPT
-
May 2019TranscriptNotesPPT
-
Mar 2019TranscriptPPT
-
Mar 2019Transcript PPT
-
Feb 2019TranscriptNotesPPT
-
Dec 2018TranscriptPPT
-
Nov 2018Transcript PPT
-
Nov 2018TranscriptNotesPPT
-
Sep 2018TranscriptPPT
-
Aug 2018Transcript PPT
-
Aug 2018TranscriptNotesPPT
-
Jun 2018TranscriptPPT
-
Jun 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Dec 2017TranscriptPPT
-
Dec 2017Transcript PPT
-
Nov 2017TranscriptNotesPPT
-
Sep 2017Transcript PPT
-
Aug 2017Transcript PPT
-
Jun 2017Transcript PPT
-
May 2017TranscriptNotesPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Jul 2016TranscriptPPT
-
Jun 2016TranscriptPPT
-
Feb 2016TranscriptPPT
About[1]
It is the largest diagnostics chain with a PAN India presence The company has 70+ yrs of experience in the field of diagnostics. The company has serviced 122 Mn+ patients
in the last 5 years.